1 April 2023  The April 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.

There are a few new/revised listings of note in the Community Schedule this month:

• Atezolizumab (Tecentriq) - new indication
• Elexacaftor with tezacaftor and ivacaftor and ivacaftor (Trikafta) - new combination product
• Pembrolizumab (Keytruda) - new indication

Read New Zealand Pharmaceutical Schedule update